Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly Replagal Dosing in Fabry Disease
NCT00068107Phase 2Completed
- Sponsor
- Baylor Scott & White Research Institute
- Start
- Sep 2003
- Primary completion
- Dec 2013
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of agalsidase alfa in Fabry disease (FD), sponsored by Baylor Scott & White Research Institute. Primary endpoint: Estimated Glomerular Filtration Rate Slope at 2 years. Started Sep 2003; status: completed.
02
Drugs
agalsidase alfa
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NCT00068107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00068107.